Lipid Manager

Mar 26, 2023

This app has been updated in accordance with the 2022 ACC ECDP on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk to incorporate newer nonstatin agents, such as bempedoic acid, evinacumab, and inclisiran. This update also includes improved risk discrimination in patient evaluation, now incorporating CAC scoring, evidence of subclinical atherosclerosis, and Familial Hypercholesterolemia.